New guide to validation of terminal sterilization process of drugs

Drug Establishment Licensing Bulletin 171, November 12, 2024

On November 12, 2024, the Health Product Compliance Directorate posted the following guidance document:

This guidance replaces the following 3 documents:

This guidance is for sterile drug fabricators who have to establish the scientific effectiveness of terminal sterilization processes. It will help them comply with Part C, Division 2 of the Food and Drug Regulations, which is about good manufacturing practices (GMP).

The principles outlined in this guidance can also apply to the sterilization of:

Health Canada developed the guidelines in consultation with stakeholders.

The guidelines are written to align with International Organization for Standardization (ISO) standards.

Key topics covered by the guidance are:

Natural health products

The principles described in GUI-0074 can be applied to natural health products. The Natural Health Products Regulations require that proper good manufacturing practices be followed to ensure that products meet the definition of a sterile product, which could include terminal sterilization.

Manufacturers, packagers, labellers and importers of sterile NHPs should follow the guidelines set out in the following guidance documents:

Contact us

If you have questions, you should contact the Health Product Inspection and Licensing Division of the Regulatory Operations and Enforcement Branch. Email us at drug.gmp.questions-bpf.medicaments@hc-sc.gc.ca.

Page details

Date modified: